Subtopic Deep Dive

← Histone Deacetylase Inhibitors Research

Non-Histone Protein Acetylation by HDACs
Research Guide

What is Non-Histone Protein Acetylation by HDACs?

Non-histone protein acetylation by HDACs refers to the deacetylation of lysine residues on non-chromatin proteins such as transcription factors, metabolic enzymes, and cytoskeletal elements by histone deacetylase enzymes.

HDACs remove acetyl groups from both histones and non-histone proteins, regulating diverse cellular processes beyond chromatin modification (Seto and Yoshida, 2014, 1905 citations). Proteomic studies identify acetylation sites on proteins like p53 and FoxO transcription factors (Glozak et al., 2005, 1562 citations). Over 370 papers explore this subtopic within HDAC research.

Curated Papers

Key Challenges

Why It Matters

HDAC-mediated deacetylation of non-histone proteins like p53 modulates tumor suppression and DNA repair, expanding HDAC inhibitor applications in cancer therapy (Seto and Yoshida, 2014). Cytoplasmic HDAC actions on metabolic enzymes influence energy homeostasis and signaling, inspiring targeted inhibitors (Glozak et al., 2005). These findings underpin combination therapies combining HDAC inhibitors with other agents for enhanced efficacy (Bayat Mokhtari et al., 2017, 2374 citations; Minucci and Pelicci, 2006, 2181 citations).

Key Research Challenges

Identifying Non-Histone Substrates

Mapping acetylation sites on thousands of non-histone proteins requires advanced proteomics, as HDACs act on diverse targets like transcription factors (Glozak et al., 2005). Current mass spectrometry misses low-abundance or transient modifications (Seto and Yoshida, 2014).

Distinguishing Histone vs Non-Histone Roles

Isolating cytoplasmic HDAC functions from nuclear effects demands compartmental-specific inhibitors, complicated by overlapping substrates (de Ruijter et al., 2003, 3060 citations). Knockout studies show pleiotropic phenotypes (Li and Seto, 2016).

Developing Selective Inhibitors

Class-specific HDAC inhibitors struggle with non-histone off-target effects in cytoplasm (West and Johnstone, 2014, 1339 citations). Balancing potency against toxicity remains unresolved (Phiel et al., 2001).

Essential Papers

Histone deacetylases (HDACs): characterization of the classical HDAC family

Annemieke J.M. de Ruijter, Albert H. Gennip, Huib N. Caron et al. · 2003 · Biochemical Journal · 3.1K citations

Transcriptional regulation in eukaryotes occurs within a chromatin setting, and is strongly influenced by the post-translational modification of histones, the building blocks of chromatin, such as ...

Epigenetics in cancer

Shilpa Sharma, T. K. Kelly, P A Jones · 2009 · Carcinogenesis · 2.5K citations

Epigenetic mechanisms are essential for normal development and maintenance of tissue-specific gene expression patterns in mammals. Disruption of epigenetic processes can lead to altered gene functi...

Combination therapy in combating cancer

Reza Bayat Mokhtari, Tina S. Homayouni, Narges Baluch et al. · 2017 · Oncotarget · 2.4K citations

Combination therapy, a treatment modality that combines two or more therapeutic agents, is a cornerstone of cancer therapy. The amalgamation of anti-cancer drugs enhances efficacy compared to the m...

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Saverio Minucci, Pier Giuseppe Pelicci · 2006 · Nature reviews. Cancer · 2.2K citations

Erasers of Histone Acetylation: The Histone Deacetylase Enzymes

Ed Seto, Minoru Yoshida · 2014 · Cold Spring Harbor Perspectives in Biology · 1.9K citations

Histone deacetylases (HDACs) are enzymes that catalyze the removal of acetyl functional groups from the lysine residues of both histone and nonhistone proteins. In humans, there are 18 HDAC enzymes...

Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen

Christopher J. Phiel, Fang Zhang, Eric Yi‐Hsiu Huang et al. · 2001 · Journal of Biological Chemistry · 1.7K citations

Valproic acid is widely used to treat epilepsy and bipolar disorder and is also a potent teratogen, but its mechanisms of action in any of these settings are unknown. We report that valproic acid a...

Acetylation and deacetylation of non-histone proteins

Michele A. Glozak, Nilanjan Sengupta, Xiaohong Zhang et al. · 2005 · Gene · 1.6K citations

Reading Guide

Foundational Papers

Read de Ruijter et al. (2003, 3060 citations) first for HDAC family classification, then Glozak et al. (2005, 1562 citations) for non-histone mechanisms, followed by Seto and Yoshida (2014, 1905 citations) for enzyme details.

Recent Advances

Li and Seto (2016, 1225 citations) covers cancer therapy implications; West and Johnstone (2014, 1339 citations) discusses emerging inhibitors.

Core Methods

Proteomics (mass spec with HDACi); mutagenesis validation; class I/II/IV HDAC assays with fluorogenic substrates.

How PapersFlow Helps You Research Non-Histone Protein Acetylation by HDACs

Discover & Search

Research Agent uses searchPapers with 'HDAC non-histone acetylation p53' to retrieve 150+ papers, then citationGraph on Seto and Yoshida (2014) reveals 500 forward citations mapping substrate networks. exaSearch uncovers proteomic datasets; findSimilarPapers extends to FoxO deacetylation studies.

Analyze & Verify

Analysis Agent runs readPaperContent on Glozak et al. (2005) to extract 20 non-histone targets, verifies claims via CoVe against de Ruijter et al. (2003), and uses runPythonAnalysis for statistical comparison of acetylation site frequencies with NumPy/pandas. GRADE scoring flags high-confidence p53 claims at A-grade.

Synthesize & Write

Synthesis Agent detects gaps in cytoplasmic HDAC inhibitor trials via contradiction flagging across Minucci and Pelicci (2006) and West and Johnstone (2014). Writing Agent applies latexEditText for methods sections, latexSyncCitations for 50 references, and exportMermaid for HDAC substrate interaction diagrams.

Use Cases

"Analyze acetylation site motifs in non-histone HDAC substrates from proteomics data"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas motif frequency plot, matplotlib visualization) → researcher gets CSV of 500 sites with statistical enrichment p-values.

"Draft review on HDAC inhibitors targeting p53 deacetylation"

Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → researcher gets compiled PDF with 30 citations and figure tables.

"Find code for HDAC substrate prediction models"

Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets 5 active repos with Jupyter notebooks for lysine acetylation prediction.

Automated Workflows

Deep Research workflow scans 100+ papers on non-histone HDACs, chains searchPapers → citationGraph → GRADE reports, yielding structured reviews with substrate tables. DeepScan applies 7-step CoVe to verify Glozak et al. (2005) claims against 50 citing papers. Theorizer generates hypotheses linking HDAC3 cytoplasmic shuttling to metabolic disease from Seto and Yoshida (2014).

Try Doxa for Non-Histone Protein Acetylation by HDACs Research

Frequently Asked Questions

What defines non-histone protein acetylation by HDACs?

HDACs deacetylate lysine residues on non-chromatin proteins including p53, FoxO, and metabolic enzymes, distinct from histone chromatin regulation (Seto and Yoshida, 2014).

What methods identify non-histone HDAC substrates?

Mass spectrometry proteomics maps acetylation sites; HDAC inhibitors like TSA reveal dynamic changes. Studies validate sites via mutagenesis (Glozak et al., 2005).

What are key papers on this topic?

Glozak et al. (2005, 1562 citations) reviews mechanisms; Seto and Yoshida (2014, 1905 citations) details 18 human HDACs acting on non-histones; de Ruijter et al. (2003, 3060 citations) characterizes classical family.

What open problems exist?

Selective inhibitors for non-histone functions; comprehensive cytoplasmic acetylomes; isoform-specific roles in signaling (West and Johnstone, 2014; Li and Seto, 2016).